Based on a 537-patient validation study, the markers appear capable of detecting early-stage disease and could be useful for monitoring high-risk populations.
Asia Genomics will make CellMax's tests, including the CellMax-DNA Genetic Cancer Risk Test Assure and the CellMax-CRC Protect Test, available immediately.
Through prospective pancreatic ductal adenocarcinoma testing, researchers saw germline mutations in new genes and in cases outside of current germline testing criteria.
Philips has teamed with Illumina and Intermountain Healthcare's Navican on informatics for precision medicine and signed a genome analytics deal with Memorial Sloan Kettering Cancer Center.
Using a new mathematical model, researchers uncovered mutational signatures related to homologous recombination deficiency in up to one-fifth of breast cancers.
New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
